Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMOX vs FOLFOX in TSER*2/*2 Esophagogastric Cancer
NCT02296671Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of pemetrexed in Esophago-Gastric Adenocarcinoma, sponsored by Washington University School of Medicine. Planned start Feb 2015; status: withdrawn.
02
Drugs
pemetrexed
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT02296671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296671.